GlaukosGKOS
About: Glaukos Corp is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma. Its product pipeline also consists of an iStent SA trabecular micro-bypass system, a two-stent product that is slightly wider than the iStent Inject and uses a different auto-injection inserter designed for use in a standalone procedure.
Employees: 907
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
162% more first-time investments, than exits
New positions opened: 55 | Existing positions closed: 21
39% more repeat investments, than reductions
Existing positions increased: 125 | Existing positions reduced: 90
20% more funds holding in top 10
Funds holding in top 10: 5 [Q2] → 6 (+1) [Q3]
11% more funds holding
Funds holding: 283 [Q2] → 313 (+30) [Q3]
7% more capital invested
Capital invested by funds: $6.66B [Q2] → $7.13B (+$473M) [Q3]
3.03% less ownership
Funds ownership: 111.72% [Q2] → 108.69% (-3.03%) [Q3]
30% less call options, than puts
Call options by funds: $19.5M | Put options by funds: $27.8M
Research analyst outlook
8 Wall Street Analysts provided 1 year price targets over the past 3 months
8 analyst ratings
Stifel Thomas Stephan 29% 1-year accuracy 5 / 17 met price target | 12%upside $175 | Buy Maintained | 31 Dec 2024 |
Truist Securities Richard Newitter 79% 1-year accuracy 33 / 42 met price target | 18%upside $185 | Buy Maintained | 18 Dec 2024 |
Wells Fargo Larry Biegelsen 63% 1-year accuracy 29 / 46 met price target | 2%downside $153 | Overweight Maintained | 11 Dec 2024 |
Citigroup Joanne Wuensch 60% 1-year accuracy 28 / 47 met price target | 4%upside $162 | Buy Upgraded | 11 Dec 2024 |
UBS Danielle Antalffy 62% 1-year accuracy 8 / 13 met price target | 16%upside $182 | Buy Initiated | 6 Dec 2024 |
Financial journalist opinion
Based on 8 articles about GKOS published over the past 30 days
